J8498 HCPCS Level II code: Antiemetic drug, rectal/suppository, not otherwise specified
J8498 is the HCPCS code for “Antiemetic drug, rectal/suppository, not otherwise specified” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J8498Antiemetic drug, rectal/suppository, not otherwise specified
Short description: Antiemetic rectal/supp nos
HCPCS · United States
Medicare details
The indicators CMS publishes with J8498 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Special coverage instructions apply
- Medicare pricing
- Drugs
- Type of service
- Medical care
- BETOS category
- Chemotherapy
- Coverage statute
- 1861s2T
- Added
- Jan 1, 2006
Where J8498 sits
- 1J codesDrugs administered other than orally
- 2Active code J8498Antiemetic drug, rectal/suppository, not otherwise specified
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J8498 mean?
J8498 is the HCPCS code for “Antiemetic drug, rectal/suppository, not otherwise specified” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J8498?
CMS lists J8498’s Medicare coverage as “Special coverage instructions apply” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J8498
All J codesJ7684Triamcinolone, inhalation solution, compounded product, administered through dme, unit dose form, per milligramJ7685Tobramycin, inhalation solution, compounded product, administered through dme, unit dose form, per 300 milligramsJ7686Treprostinil, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, 1.74 mgJ7699Noc drugs, inhalation solution administered through dmeJ7799Noc drugs, other than inhalation drugs, administered through dmeJ7999Compounded drug, not otherwise classifiedJ8499Prescription drug, oral, non chemotherapeutic, nosJ8501Aprepitant, oral, 5 mgJ8502Injection, aprepitant (aponvie), 1 mgJ8510Busulfan; oral, 2 mgJ8515Cabergoline, oral, 0.25 mgJ8520Capecitabine, oral, 150 mg